CRAd-S-RGD exhibits enhanced oncolytic potency. U87MG, U118MG, U373MG, A172 and No. 10 glioma cells were infected with CRAd-S-RGD, AdRGD, or AdWT at the indicated doses (MOI/cell). After 10 days, adherent cells were stained with crystal violet. Data are representative examples of two independent sets of experiments.